Connect with us

Technology

UF/IFAS, Florida Strawberry Industry, and Ohalo Join Forces to Combat Devastating Fungal Disease

Published

on

APTOS, Calif., Dec. 20, 2024 /PRNewswire/ — Ohalo Genetics, Inc. has entered into a groundbreaking Development & Commercialization Agreement with the University of Florida’s Institute of Food and Agricultural Sciences, Florida Foundation Seed Producers, Inc., and the Florida Strawberry Growers Association (FSGA) to address the significant threat of neopestalotiopsis to the strawberry industry.

This fungal disease, which can wipe out entire strawberry fields, has become one of the most damaging issues faced by Florida strawberry growers, affecting crop yields, increasing production costs and threatening the livelihood of farmers in a state known as the “Winter Strawberry Capital of the United States“.

Neopestalotiopsis was first detected in Florida in 2017, with notable outbreaks in subsequent years. By 2019 and 2020, the disease had become widespread and severely damaged the crop across the state.

Currently, there are no commercially available public strawberry varieties resistant to neopestalotiopsis. Growers have relied on fungicides and rigorous field management practices to mitigate the disease’s effects, but these methods come with increased costs and limited effectiveness.

In response to this challenge, Ohalo® leveraged its advanced breeding technology platform with genetic resources from UF/IFAS to develop a novel trait that makes a strawberry plant resistant to neopestalotiopsis and integrated that trait into existing University of Florida strawberry varieties. These new, resistant varieties will enter non-commercial, experimental trials in 2025.

“This collaboration showcases the power of public-private partnerships in solving critical agricultural challenges,” said Jud Ward, CTO of Ohalo. “The Florida strawberry industry approached us with the urgent need to tackle neopestalotiopsis, a disease that devastates crops. We were proud to step up to the challenge, and by working with the Florida partners, we’re leveraging our proprietary advanced breeding system alongside their deep agricultural expertise to create a sustainable, long-term solution.”

This partnership is set to deliver significant advantages for Florida’s strawberry growers:

Mitigating Crop Losses: Neopestalotiopsis has been responsible for substantial yield reductions, with affected fields experiencing severe damage. By introducing resistant varieties, growers can markedly decrease these losses, leading to more stable and increased yields.Reducing Production Costs: Currently, managing neopestalotiopsis relies on the use of fungicides and rigorous field management practices, which can be costly, have limited efficacy, and are labor-intensive. The adoption of resistant varieties will lessen dependence on these measures, resulting in cost savings on chemical inputs and labor.Enhancing Fruit Quality: Healthier plants are better positioned to produce high-quality fruit. By mitigating the stress and damage caused by neopestalotiopsis, the new resistant varieties can lead to improvements in fruit size, shelf life, and overall marketability, benefiting both growers and consumers.Promoting Sustainable Farming Practices: The development and adoption of disease-resistant varieties align with sustainable agriculture goals, offering a long-term, environmentally friendly approach to disease management.

A shared commitment to Florida strawberries

The funding for this groundbreaking initiative comes from across the Florida strawberry industry, reflecting the unified commitment to safeguarding this vital crop. By integrating Ohalo’s advanced breeding technologies with the expertise of the Florida partners, this partnership is poised to secure the future of strawberry farming in the state.

“This is a vital partnership to achieve a timely solution for the benefit of our industry that would not have otherwise been possible,” said Vance Whitaker, professor of horticultural sciences at UF/IFAS, who is working on this project in collaboration with Seonghee Lee, associate professor of horticultural sciences at UF/IFAS.

“This partnership is about more than just research; it’s about delivering real solutions to the fields in Florida through public-private partnership,” said John Beuttenmuller, executive director of Florida Foundation Seed Producers, Inc., a non-profit corporation responsible for the technology transfer of plant genetics developed at UF/IFAS. “Our collaboration with Ohalo means that growers will have access to resilient varieties, ensuring that Florida strawberries remain a staple for years to come.” 

Kenneth Parker, executive director of the Florida Strawberry Growers Association, said, “The Florida strawberry industry has always been innovative, and this initiative will create effective solutions to ensure the continued success of the Florida strawberry industry, a significant contributor to Florida’s economy, with a total economic impact of about $1 billion.”

As neopestalotiopsis continues to pose a threat to strawberry production, this collaboration represents a significant step forward in ensuring the resilience and prosperity of Florida’s strawberry industry.

For more information about Ohalo, visit www.ohalo.com.

About Ohalo
Ohalo® aims to accelerate evolution to unlock nature’s potential. Founded in 2019, Ohalo develops novel breeding systems and improved plant varieties that help farmers grow more food with fewer natural resources, increasing the yield, resiliency, and genetic diversity of crops to sustainably feed our population. Ohalo’s breakthrough technology, Boosted Breeding™, will usher in a new era of improved productivity to radically transform global agriculture. For more information, visit www.ohalo.com.

About The Florida Partners

UF/IFAS
UF/IFAS carries on a comprehensive strawberry research, extension, and teaching program throughout the State of Florida, including strawberry breeding and genetics research at the UF/IFAS Gulf Coast Research and Education Center near Plant City, FL. UF/IFAS-developed strawberry varieties account for nearly 90% of the strawberries grown in Florida.

FFSP
Florida Foundation Seed Producers, Inc. is a non-profit corporation and direct support organization of the University of Florida. FFSP is responsible for all technology transfer aspects for new plant genetics developed by UF/IFAS plant breeders. Over the past twenty years, FFSP has received more than 540 new invention disclosures and issued more than 2,800 patent license agreements to bring new plant innovation to market while also supporting the preeminent plant breeding programs at UF/IFAS.

FSGA
The Florida Strawberry Growers Association is a non-profit organization that was founded by a group of Florida strawberry growers in 1982 to represent the interests of the Florida strawberry industry. Through its sister organization, the Florida Strawberry Research and Education Foundation, it works to support strawberry research at UF/IFAS.  Its other sister organization, the Florida Strawberry Patent Service, works to obtain licenses from FFSP and then sublicense nurseries for the production of patented varieties developed at UF/IFAS.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ufifas-florida-strawberry-industry-and-ohalo-join-forces-to-combat-devastating-fungal-disease-302337089.html

SOURCE Ohalo Genetics, Inc

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

Published

on

By

BEIJING, April 23, 2026 /PRNewswire/ — Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 31, 2026, before the U.S. market opens on May 18, 2026. Baidu’s management will hold an earnings conference call at 8:00 AM on May 18, 2026, U.S. Eastern Time (8:00 PM on May 18, 2026, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of “Baidu Inc. Q1 2026 Earnings Conference Call”. Please follow the steps to enter your registration details, then click “Register”. Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10054331-iu876y.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com.

A replay of the conference call may be accessed by phone at the following number until May 25, 2026:
US: 1 855 883 1031
Reply PIN: 10054331

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and the HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

View original content:https://www.prnewswire.com/news-releases/baidu-to-report-first-quarter-2026-financial-results-on-may-18-2026-302751204.html

SOURCE Baidu, Inc.

Continue Reading

Technology

Phase 1 of 139th Canton Fair Introduces New Dedicated Product Zones as Emerging Technologies Take Center Stage

Published

on

By

GUANGZHOU, China, April 23, 2026 /PRNewswire/ — The 139th China Import and Export Fair (Canton Fair) has further optimized its exhibition landscape with nine new dedicated product zones, reflecting ongoing structural shifts in global trade and the continued upgrading of China’s export portfolio.

Among the most closely watched additions in Phase 1 are the consumer and agricultural drone zones, both making their debut at the Canton Fair and offering a focused showcase of applications in the low‑altitude economy. The consumer drone zone showcases progress in flight control, AI‑based obstacle avoidance and energy efficiency across imaging, tourism, emergency response and patrol. The agricultural drone zone highlights precision farming, with spraying, seeding and field‑management demonstrations showing terrain‑following, intelligent route planning, and precise payload control.

On day one, a Shandong‑based drone manufacturer welcomed buyers from 30+ countries, with over 50 strong leads. One buyer, after seeing load and wind‑resistance demonstrations, immediately confirmed three sample units and even proposed becoming a regional distributor.

Display technology is another focal point of Phase 1, highlighting advances in color accuracy, energy efficiency, and overall visual performance. Developments in fine‑grained control, expanded color gamut, and reduced power consumption point to a clear trend toward immersive viewing experiences combined with sustainability gains.

The smart wearables zone underscores how intelligent devices are becoming key interfaces for human‑machine interaction. From real‑time language translation and adaptive noise cancellation to long‑term health monitoring and AI‑enabled eyewear, wearables are evolving from standalone products into integrated systems that support communication, well‑being, and productivity across daily and professional settings.

The service robots zone further illustrates how artificial intelligence is moving from conceptual exploration to large‑scale deployment. Advanced robots showcased across industrial, commercial, medical, and public‑service scenarios demonstrate growing autonomy, multi‑sensory perception, and closer human-robot collaboration.

By bringing emerging technologies into clearer focus through dedicated zones, the 139th Canton Fair is reinforcing its function as a platform where trade trends take shape, innovation meets application, and global buyers gain early insights into cutting-edge technologies.

For pre-registration, please click: https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Photo – https://mma.prnewswire.com/media/2963958/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/phase-1-of-139th-canton-fair-introduces-new-dedicated-product-zones-as-emerging-technologies-take-center-stage-302751520.html

Continue Reading

Technology

OZMOSI Announces Strategic Partnership with Planview to Advance AI-Driven Planning in Pharmaceutical R&D

Published

on

By

By combining structured clinical intelligence with AI-driven portfolio planning, the partnership gives pharmaceutical teams a faster, clearer way to make high-stakes R&D decisions

SPRING LAKE HEIGHTS, N.J., April 23, 2026 /PRNewswire/ — OZMOSI, a leading provider of structured pharmaceutical development intelligence, today announced a strategic partnership with Planview, the leading AI-powered end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD).

By integrating OZMOSI’s machine-readable clinical datasets directly into Planview’s AI-driven portfolio planning platform, external scientific data is now connected to internal R&D planning in one system,  helping pharmaceutical organizations better predict market shifts, prioritize R&D investments, and make faster, more confident decisions.

This integration brings external clinical reality into internal R&D decision-making, so teams can plan based on what’s actually happening, not just on what they hope will happen.

The two organizations combine deep expertise in complementary areas, united by a shared focus on improving the quality and usability of data for strategic decision-making. OZMOSI provides structured, machine-readable intelligence across clinical trials, drug development programs, regulatory activity, and scientific literature, built on a consistent taxonomy that standardizes how data is connected and understood. Planview’s platform enables organizations to model complex investment scenarios, align initiatives with corporate strategy, and optimize resource allocation.

Together, these capabilities give teams a clearer, more complete view of the R&D landscape, grounded in clean, standardized data and strengthened by AI-driven analysis.

“AI is only as powerful as the data that fuels it,” said Beau Bush, President and Founder of OZMOSI. “Pharmaceutical organizations have no shortage of data, but too often it’s fragmented, inconsistent, and difficult to operationalize. By bringing OZMOSI’s structured data foundation together with Planview’s AI-driven planning capabilities, we’re enabling teams to move beyond disconnected analysis and toward truly integrated, forward-looking decision-making.”

“Strategic planning in pharmaceutical R&D is becoming increasingly dependent on advanced analytics and AI,” said  Louise Allen, Chief Product Officer at Planview. “Integrating OZMOSI’s clinical intelligence into Planview’s platform enables pharmaceutical leaders to make better decisions by combining trusted external data with AI-driven planning

OZMOSI’s dataset spans more than 800,000 clinical trials, over 35,000 drugs, and 4,000 diseases and conditions. It brings together insights from clinical trial registries, regulatory filings, scientific literature, company disclosures, and industry announcements into a unified, structured dataset.

When integrated into Planview’s platform, this intelligence enables pharmaceutical and biotech organizations to evaluate competitive landscapes, identify emerging clinical trends, and simulate portfolio outcomes with unprecedented precision.

Together, OZMOSI and Planview are redefining how pharmaceutical organizations approach R&D strategy, ensuring that investment decisions are guided by accurate, standardized, and AI-ready data. By combining internal portfolio visibility with a continuously updated external view of the market, the partnership helps leaders not only understand what they have, but what to do next.

About OZMOSI

Founded in 2013, OZMOSI specializes in transforming complex pharmaceutical R&D intelligence into structured, machine-readable data. The company provides the foundation needed for accurate competitive analysis, product forecasting, and portfolio strategy. Through its proprietary taxonomy and semantic layer, OZMOSI connects fragmented data across the pharmaceutical ecosystem, enabling faster, more confident decision-making for global pharma, biotech, and investment teams.

Based in Spring Lake Heights, New Jersey, OZMOSI is focused on making pharmaceutical intelligence clear, usable, and ready for the future of AI-driven strategy. Learn more at www.ozmosi.com.

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD), powered by advanced AI capabilities that give business and technology leaders the strategic foresight to prioritize investments and initiatives, make plans real within constraints, and pivot with certainty when things change. Our AI-driven connected platform of solutions underpins the business and digital transformations of more than 3,000 customers and 3.1 million users globally. Headquartered in Austin, Texas, Planview has over 1,500 employees worldwide. Learn more at www.planview.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ozmosi-announces-strategic-partnership-with-planview-to-advance-ai-driven-planning-in-pharmaceutical-rd-302750944.html

SOURCE Ozmosi Company

Continue Reading

Trending